TAIGEN BIOTECHNOLOGY
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
TaiGen Successfully Completes TG-1000 Phase III Study 2024-04-18 11:03
TaiGen Enters Exclusive License Agreement with YSP 2023-10-11 11:24
TaiGen Partners with GPCR to develop Burixafor & Taigexyn(R) 2020-11-09 18:22
TaiGen Announces FDA Approval of IND for Its Flu Antiviral TG-1000 2020-11-02 07:30
TaiGen filed US IND for its influenza antiviral TG-1000 2020-10-05 06:50
TaiGen Biotechnology Out-Licensed Taigexyn (Nemonoxacin) to Luminarie Canada for Canada, Australia and New Zealand 2020-09-30 15:51
HEC TaiGen Initiates Phase III Trial of Combination of Furaprevir and Yimitasvir for the Treatment of Chronic Hepatitis C Patients in China 2019-04-23 15:58
TaiGen Biotechnology Announces Submission of New Drug Application for Taigexyn® Intravenous Formulation to the China Food and Drug Administration 2017-05-30 13:15
TaiGen Biotechnology and HEC Pharmaceutical Executed Equity Purchase Agreement for Their HCV Joint Venture 2017-03-27 17:24
TaiGen Biotechnology To Establish a New Company With HEC Pharmaceutical in China for Treatment of Chronic Hepatitis C 2016-10-30 20:18
TaiGen Biotechnology Out-Licenses Taigexyn(R) (Nemonoxacin) to Productos Científicos for the Latin American Market 2016-08-25 17:49
TaiGen Biotechnology Receives Market Approval from the China Food and Drug Administration for Taigexyn(R) (nemonoxacin) 2016-06-13 23:30
TaiGen Biotechnology Launches Taigexyn(R) in Taiwan 2015-12-16 11:02
TaiGen's Intravenous Taigexyn(R) Successfully Achieved Primary Endpoint in Phase 3 Clinical Trial for Community Acquired Pneumonia 2015-12-03 19:04
TaiGen Biotechnology Announces Initiation of Burixafor Chemosensitization Clinical Trial in Acute Myeloid Leukemia in China 2015-04-30 13:17
TaiGen Biotechnology Receives Marketing Approval from the Taiwan Food and Drug Administration for Taigexyn(R) (nemonoxacin) in Taiwan 2014-03-13 17:22
TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2014-01-15 15:00
TaiGen Biotechnology Receives Qualified Infectious Disease Product and Fast Track Designations from the U.S. Food and Drug Administration for Nemonoxacin (Taigexyn(R)) 2013-12-23 15:00
TaiGen Biotechnology Reports Phase IIa Data for TG-0054 at the 2013 American Society of Hematology (ASH) Annual Meeting 2013-10-30 09:46
TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine 2012-06-25 14:00
1 2